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ABSTRACT The II-III cytoplasmic loop of the skeletal muscle dihydropyridine receptor (DHPR) 1-subunit is essential for
skeletal-type excitation-contraction coupling. Single channel and [3H]ryanodine binding studies with a full-length recombinant
peptide (p666–791) confirmed that this region specifically activates skeletal muscle Ca2 release channels (CRCs). However,
attempts to identify shorter domains of the II-III loop specific for skeletal CRC activation have yielded contradictory results.
We assessed the specificity of the interaction of five truncated II-III loop peptides by comparing their effects on skeletal and
cardiac CRCs in lipid bilayer experiments; p671–680 and p720–765 specifically activated the submaximally Ca2-activated
skeletal CRC in experiments using both mono and divalent ions as current carriers. A third peptide, p671–690, showed a
bimodal activation/inactivation behavior indicating a high-affinity activating and low-affinity inactivating binding site. Two
other peptides (p681–690 and p681–685) that contained an RKRRK-motif and have previously been suggested in in vitro studies
to be important for skeletal-type E-C coupling, failed to specifically stimulate skeletal CRCs. Noteworthy, p671–690, p681–690,
and p681–685 induced similar subconductances and long-lasting channel closings in skeletal and cardiac CRCs, indicating that
these peptides interact in an isoform-independent manner with the CRCs.
INTRODUCTION
Excitation-contraction (E-C) coupling in striated muscle is a
signal transduction event that leads to the activation of
sarcoplasmic reticulum (SR) Ca2 release channels (CRCs,
also known as ryanodine receptors or RyRs). In mammalian
skeletal muscle, this process is thought to be mediated by a
direct physical interaction between dihydropyridine-sensi-
tive (L-type) Ca2 channels (dihydropyridine receptors or
DHPRs), located in the surface membrane and tubular in-
foldings (T-tubule), and the CRCs (Rios and Pizarro, 1991).
In contrast to its role as a voltage-sensor in skeletal muscle,
the cardiac DHPR isoform mediates an influx of Ca2 ions
that open closely apposed CRCs in cardiac muscle. The
skeletal CRC is a large channel composed of four large
565-kDa subunits and four small 12-kDa FK506 binding
proteins (Coronado et al., 1994; Meissner, 1994; Franzini-
Armstrong and Protasi, 1997; Ondrias et al., 1998). The
mammalian skeletal muscle DHPR is composed of five
subunits, 1, 2, , , and  (Catterall, 1995). Co-immuno-
precipitation (Marty et al., 1994) and cross-linking of the
skeletal muscle DHPR and CRC (Murray and Ohlendieck,
1997) as well as morphological evidence (Block et al.,
1988) suggest a well-defined interaction between the two
receptors. Clusters of four particles called tetrads that rep-
resent four DHPRs are located opposite the four subunits of
every other RyR (Block et al., 1988). The clustering of
DHPRs into tetrads is dependent on the presence of the
skeletal CRC (Protasi et al., 1998), whereas their targeting
to junctional domains of T-tubules is not (Takekura and
Franzini-Armstrong, 1999).
Microinjection of skeletal and cardiac cDNAs and their
chimeric constructs into dysgenic myotubes that lack the
skeletal muscle DHPR 1-subunit first suggested that the
cytosolic II-III loop region (residues 666–791) of the DHPR
1 subunit is responsible for mediating skeletal-type E-C
coupling (Tanabe et al., 1990). A recombinant peptide cor-
responding to the II-III loop increased [3H]ryanodine bind-
ing to skeletal muscle SR vesicles and increased skeletal,
but not cardiac, CRC activity in single channel experiments,
thus implying that the II-III loop region may specifically
and directly interact with the skeletal CRC (Lu et al., 1994).
Synthetic peptides corresponding to different regions of the
II-III loop have been used to narrow the amino acid residues
required to activate the skeletal CRC. Peptide671–690 and
p681–690 increased [3H]ryanodine binding to and increased
Ca2 release from skeletal muscle SR vesicles (El-Hayek et
al., 1995; El-Hayek and Ikemoto, 1998). Single channel
measurements confirmed an interaction of p671–690 with the
skeletal CRC (Dulhunty et al., 1999; Gurrola et al., 1999).
A second regulatory region in the DHPR 1-subunit II-III
loop was identified using a peptide corresponding to Glu724-
Pro760 that by itself had no effect, but which blocked the
activating effects and conformational changes induced by
p671–690 or T-tubule depolarization (El-Hayek et al., 1995;
Saiki et al., 1999). Microinjection of skeletal and cardiac
muscle chimeric cDNAs into dysgenic myotubes indicated
that skeletal residues 711–765, and to a lesser extent resi-
dues 725–742, were sufficient to evoke skeletal-type E-C
coupling (Nakai et al., 1998). Noteworthy, the in vivo
studies challenged the results obtained with a DHPR-de-
rived peptide corresponding to the N-terminal part of the
II-III loop, as this region did not appear to be critical for
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skeletal muscle E-C coupling (Nakai et al., 1998; Proenza et
al., 2000). Additional regions of the DHPR 1-subunit
(Leong and MacLennan, 1998; Slavik et al., 1997) and the
-subunit of the DHPR (Beurg et al., 1999) have been
reported to contribute to the functional coupling of the
skeletal DHPR and CRC.
In the present study, we examined the effects of the
full-length II-III loop peptide (p666–791) and five shorter
peptides (p671–690, p671–680, p681–690, p681–685, p720–765)
(Fig. 1) on single skeletal and cardiac muscle CRCs. Iso-
form-specificity and regulation of channel activity were
determined in single channel measurements using submaxi-
mally and maximally Ca2-activated CRCs with 250 mM
KCl as current carrier. Our results indicate that the full-
length II-III loop peptide and two shorter regions (p671–680
and p720–765) specifically activate the submaximally Ca2-
activated skeletal CRC in a concentration-dependent man-
ner. Activation of skeletal CRCs by p671–680 and p720–765
was confirmed in experiments using Ca2 as current carrier.
We also present evidence that a region (p681–690), previ-
ously proposed to be critical for skeletal-type E-C coupling,
fails to significantly activate submaximally Ca2-activated
skeletal CRCs. Rather, this peptide induced similar subcon-
ductance states in both the skeletal and cardiac CRC, which
suggests an isoform-independent action.
MATERIALS AND METHODS
Materials
Phospholipids were obtained from Avanti Polar Lipids (Birmingham, AL).
The recombinant DHPR 1-subunit full-length II-III loop peptide was
expressed and purified as described (Lu et al., 1994). The truncated II-III
loop peptides were synthesized and purified in the Molecular Biology and
Biotechnology Micro-Protein Chemistry Facility at the University of North
Carolina. All other chemicals were of analytical grade.
Preparation of heavy SR vesicles and
purification and reconstitution of Ca2
release channels
SR vesicle fractions enriched in [3H]ryanodine binding and Ca2-
release channel activities were prepared from rabbit skeletal and canine
cardiac muscle in the presence of protease inhibitors (100 nM aprotinin,
1 M leupeptin, 1 M pepstatin, 1 mM benzamidine, 0.2 mM phenyl-
methylsulfonyl fluoride) (Meissner, 1984; Meissner and Henderson,
1987). The 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesul-
fonate (CHAPS)-solubilized skeletal and cardiac muscle 30S CRC
complexes were isolated by rate density gradient centrifugation and
reconstituted into proteoliposomes by removal of CHAPS by dialysis
(Lee et al., 1994). Proteoliposomes were sedimented by centrifugation,
resuspended in 0.3 M sucrose, 5 mM KPipes, pH 7.4, quick-frozen in
small aliquots, and stored at 80°C.
Single channel measurements
Unless otherwise indicated, single channel recordings were performed in
symmetric KCl solutions (250 mM, 10 mM KHepes, pH 7.3) containing
additions as indicated. Proteoliposomes containing the purified skeletal or
cardiac muscle CRCs were added to the cis chamber of a bilayer apparatus
and fused in the presence of an osmotic gradient with Mueller-Rudin type
planar bilayers containing a 4:1 mixture of bovine brain phosphatidyleth-
anolamine and phosphatidylcholine (30–40 mg of total phospholipid/ml
n-decane). Unless otherwise indicated, the gradient was formed across the
bilayer membrane with 250 mM cis KCl and 20 mM trans KCl solutions.
After appearance of single channel activity, an increase in trans KCl
concentration to 250 mM prevented further fusion of proteoliposomes. The
number of channels incorporated in the bilayer was determined in the
presence of maximally Ca2-activating conditions (see Fig. 8). For exper-
iments using submaximally Ca2-activating CRCs, the free Ca2 concen-
tration was subsequently lowered to 1 M. The trans side of the bilayer
was defined as ground. Measurement of the sensitivity of the channels to
M cytosolic Ca2 indicated that in a majority of recordings (98%) the
cytosolic side of the CRC faced the cis side and the lumenal side faced the
trans side of the bilayer. Peptides were added to the cis (cytosolic) side of
the bilayer from stock solutions made in 250 mM KCl, 10 mM KHepes, pH
7.3 solution. To test the possibility that added peptides bind to the bilayer
chamber or associate with the membrane and thereby reduce the concen-
tration of free peptide, we verified calculated concentrations spectropho-
tometrically for peptide concentrations 1 M. Similarly, we ensured
spectrophotometrically using antipyrazolo III that all peptides used in this
study did not bind Ca2, and thereby lower the free Ca2 concentration at
higher doses. After a stirring period of 60 s, channel activities were
recorded at 40 mV and 40 mV holding potential using a commercially
available patch-clamp amplifier with a bilayer headstage (Axopatch 1D,
Axon Instruments, Burlingame, CA). Unless otherwise indicated, record-
ings were filtered at 4 kHz through an eight-pole low-pass Bessel filter
(Frequency Devices, Inc., Haverhill, MA) and digitized at 20 kHz. Data
acquisition and analysis were performed with the software package
pClamp 6.0.1. (Axon Instruments) using an IBM-compatible computer and
a 12 bit A/D - D/A converter (Digidata 1200, Axon Instruments). Data files
were directly acquired using the continuous Fetchex mode. Channel pa-
rameters were calculated from current recordings of 2 min duration (Tri-
pathy and Meissner, 1996). Because all peptides used in this study, with the
exception of p681–685 (Fig. 6), lacked subconductances 50% in submaxi-
mally Ca2 activating conditions and amplitude histogram analysis indi-
cated that subconductances contributed to 10% of the overall open
events, channel open probability (Po) was obtained by setting the threshold
level at 50% of the current amplitude between the closed and open states.
Po values in multichannel recordings were calculated using the formula 
iPo,i/N, where N is the total number of channels, and Po,i is channel open
probability of the ith channel. Mean PoControl values  SE for submaxi-
mally Ca2-activated skeletal CRCs were 0.0168  0.002 (40 mV; n 	
127); 0.0163  0.002 (40 mV, n 	 127); 0.0069  0.002 (0 mV, n 	
27). Submaximally Ca2-activated cardiac CRCs exhibited mean Po values
of 0.037  0.012 (40 mV, n 	 42) and 0.036  0.012 (40 mV, n 	
42) in the absence of peptide. Reversibility of channel activation induced
by the activating peptides was verified by a decrease of activity following
perfusion of the chamber solution. The positions of substates relative to the
fully open amplitude were determined using current amplitude histograms
FIGURE 1 Amino acid sequence of cytoplasmic DHPR 1 subunit II-III
loop. Peptides used in this study are indicated by numbering the amino
acids that correspond to the first and last residue of the peptides.
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obtained from 2-min single channel recordings and visual inspection of the
corresponding current traces. The positions of the major subconductances
in each histogram were obtained by best-fitting Gaussian curves to the
current amplitude histograms.
Determination of free Ca2 concentrations
Different free Ca2 concentrations were prepared by mixing CaCl2 and
EGTA as determined using the stability constants and computer program
published by Schoenmakers et al. (1992). Free Ca2 concentrations were
verified using a Ca2-selective electrode (World Precision Instruments,
Inc., Sarasota, FL).
Data analysis
Results are given as mean  SE with the number of experiments in
parentheses. Unless otherwise indicated, significance compared to the
control group (channel activity in the absence of peptide) was determined
using one-way analysis of variance (ANOVA) followed by a post hoc test
(Dunnett’s method) in cases where ANOVA demonstrated statistical
significance. Differences were regarded to be statistically significant at
p  0.05.
RESULTS
Effects of full-length II-III loop peptide on
submaximally Ca2-activated skeletal and
cardiac CRCs
Previous studies have shown that the cytoplasmic II-III loop
of the DHPR 1-subunit has a key role in mediating skel-
etal-type E-C coupling (Tanabe et al., 1990; Lu et al., 1994).
In preliminary studies we confirmed that the full-length
II-III loop peptide activates skeletal but not cardiac CRCs.
Fig. 2 A shows the results of a representative channel
recording using skeletal CRC. A single channel was re-
corded at 40 mV and 40 mV holding potentials in
symmetric 250 mM KCl medium containing a submaxi-
mally activating concentration of 1 M cytosolic free
Ca2. The lumenal Ca2 concentration in all experiments
investigating submaximally Ca2-activated CRCs was 1
M to minimize lumenal to cytosolic Ca2 fluxes through
the CRC (Tripathy and Meissner, 1996). The two top traces
show a low channel open probability (Po) for skeletal CRC
in the absence of the II-III loop peptide and are character-
ized by a low number of brief, often not fully resolved open
events, shown as upward and downward deflections from
the closed state (marked “C”). Addition of 100 nM II-III
loop peptide to the cytosolic (cis) side of the bilayer in-
creased Po 1.3- and 3-fold (second two traces). A further
increase in Po was observed at both holding potentials as the
cytosolic II-III loop peptide concentration was raised from
100 nM to 750 nM and 3 M (third and last recordings).
Clearly defined subconductances were not detected at either
holding potential. The peptide-induced increase in Po was
due to an increase in the number of events, as there was no
change in the mean open time of the channel openings in the
presence of peptide. The mean relative increase in Po of the
skeletal CRC as a function of cytosolic peptide concentra-
tion from four to nine experiments is shown in Fig. 2 B
(circles). The normalized Po values reached a maximum
level (7-fold) at both holding potentials at a peptide con-
centration of 3 M, and slightly declined as the peptide
concentration was raised to 7.5 M.
The effects of the II-III loop peptide in single channel
measurements were initially studied in our laboratory (Lu et
al., 1994) using CHAPS-solubilized skeletal CRCs. The
previous data indicated a much greater level of activation of
the skeletal CRC due to an increase in both frequency of
open events and mean open time. However, because subse-
quent studies have indicated that residual CHAPS in the
lipid bilayer can alter channel response and evoke non-
FIGURE 2 DHPR full-length II-III loop peptide specifically activates
the submaximally Ca2-activated skeletal muscle CRC. (A) Shown are
eight recordings from one experiment with a single skeletal CRC. Single
channel currents, shown as upward or downward deflections from closed
levels (marked “C”), were recorded in symmetric 250 mM KCl, 10 mM
KHepes, pH 7.3. The cis (cytosolic) and trans (lumenal) free Ca2 was1
M. Current recordings were measured at 40 mV (left panel) and 40
mV (right panel) holding potential at 0 (Control), 100 nM, 750 nM and 3
M p666–791. (B) Relative mean Po values (SE) from four to nine
experiments using skeletal (circles) and from three to six experiments
using cardiac (squares) CRCs at different peptide concentrations and
recorded at holding potentials of 40 mV (open symbols) and 40 mV
(closed symbols). *Significantly different (p  0.05) from control as
determined by ANOVA and Dunnett’s method.
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physiological effects (Xiong et al., 1998), all current exper-
iments were performed using reconstituted liposomes. Fig.
2 B also summarizes data (not shown) using cardiac CRCs
at a submaximally activating free Ca2 concentration of1
M. In contrast to the skeletal CRC, the full-length II-III
loop peptide did not activate the cardiac CRC (Fig. 2 B,
squares).
Effects of truncated II-III loop peptides on
submaximally Ca2-activated skeletal and
cardiac CRCs
The effects of shorter peptides corresponding to different
regions of the II-III loop were investigated to assess the
specificity of their CRC interactions and to determine the
minimum sequences that mediate skeletal-type E-C cou-
pling. Minimally Ca2-activated skeletal and cardiac CRCs
(1 M free Ca2) were used to test for activating effects
of the peptides with K as current carrier. Neither the
full-length nor the truncated II-III loop peptides had any
effect on the unmodified bilayer. Concentration-dependent
stimulation by two truncated peptides was confirmed with
Ca2 as the current carrier and using physiological KCl
concentrations of 150 mM. Because some of the peptides
caused inhibition of channel activity and the appearance of
subconductance states, we also explored their effects on
maximally Ca2-activated channels.
Peptide671–690
Peptide671–690 corresponds to the N-terminal region of
the II-III loop (Fig. 1) and was previously found to
contain a critical sequence for mediating skeletal-type
E-C coupling (El-Hayek et al., 1995; El-Hayek and Ike-
moto, 1998; Dulhunty et al., 1999). We found that
p671–690 displayed activating and inhibiting effects on the
skeletal CRC caused by an increase and subsequent de-
crease in the frequency of open events. In Fig. 3 A,
addition of 30 nM p671–690 activated a single skeletal
CRCs at 40 mV and 40 mV holding potentials. In-
creasing p671–690 concentration to 3 M preserved chan-
nel activity, whereas further increase in peptide concen-
tration to 30 M decreased Po at both holding potentials.
Low-conductance substates (arrows) were identified at
40 mV at peptide concentrations in excess of 0.5 M
(Fig. 3 A, third and bottom traces, left panel). The ability
of p671–690 to induce subconductances in skeletal and
cardiac CRCs is analyzed in greater detail in Fig. 8, A and
B, respectively, using maximally Ca2-activated chan-
nels.
Fig. 3 B shows the mean relative changes in Po values
calculated from 13 to 16 experiments with skeletal CRCs
plotted as a function of peptide concentration. A broad
plateau of maximal channel activation was observed in the
presence of 30 nM to 3 M peptide, indicating a high
affinity activation site. Higher peptide concentrations (10
and 30 M at 40 mV and 30 M at 40 mV) resulted in
a significant decrease in channel activity compared to levels
observed in the presence of 0.1 M to 3 M and 0.3 M
peptide concentration, respectively. Significance was deter-
mined as described in the Materials and Methods section
using one-way ANOVA analysis followed by the LSD
method as post hoc test.
Like the full-length p666–791, p671–690 failed to activate
the submaximally Ca2-activated cardiac CRC and caused a
slight decrease in channel activity at concentrations1 M
(Fig. 3 B, squares) due to a decreased number of open
events. Subconductance states similar to those observed in
submaximally Ca2-activated skeletal channels (Fig. 3 A,
left panel) were observed at 40 mV and at peptide con-
centrations of 3 M (not shown).
FIGURE 3 Effects of p671–690 on submaximally Ca2-activated skeletal
and cardiac CRCs. (A) Shown are eight recordings from one experiment
with 1 skeletal CRCs at 0 (Control) and the indicated peptide concentra-
tions. Single channel currents, shown as upward or downward deflections
from closed levels (marked “C”), were recorded as in Fig. 2. (B) Relative
mean Po values (SE) from 13 to 16 experiments using skeletal (circles)
and from four to five experiments using cardiac (squares) CRCs at differ-
ent peptide concentrations and recorded at holding potentials of 40 mV
(open symbols) and 40 mV (closed symbols). *Significantly different
(p  0.05) from control as determined by ANOVA and Dunnett’s method.
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Peptide671–680
Fig. 4, A and B show the effects of p671–680 (N-terminal half
of p671–690) on submaximally Ca2-activated skeletal and
cardiac CRCs with K as current carrier. The channel traces
of three skeletal CRCs are shown in Fig. 4 A, and the mean
relative changes in Po values obtained from 6 to 15 exper-
iments as a function of peptide concentration are shown in
Fig. 4 B. Peptide671–680 significantly activated the skeletal
CRC at micromolar concentrations increasing channel ac-
tivities 6-fold at 40 and 40 mV holding potentials
(Fig. 4 B, circles). Peptide671–680 did not activate the cardiac
CRC, rather the channels were significantly inhibited in the
presence of micromolar peptide concentrations (Fig. 4 B,
squares). For both isoforms modification of channel activity
was due to an increase (skeletal) or decrease (cardiac CRCs)
in the number of open events rather a change in mean open
time. Unlike p671–690 or p681–690, elevated concentrations of
p671–680 did not induce subconductance states in the sub-
maximally Ca2-activated skeletal CRC (bottom traces in
Fig. 4 A) or cardiac CRC (not shown). The lack of subcon-
ductances was confirmed using maximally Ca2-activated
skeletal and cardiac CRCs (data not shown).
Stimulation of submaximally Ca2-activated skeletal
CRCs was confirmed at 0 mV holding potential under more
physiological conditions using symmetrical 150 mM KCl
solution and 10 mM lumenal Ca2 as current carrier. Fig. 4
C summarizes data from 8 to 11 experiments with 3, 10, and
30 M cytosolic p671–680. The results suggest a concentra-
tion-dependent agonist function of p671–680 leading to an
3-fold increase in activity of the skeletal CRC at micro-
molar peptide concentrations.
Peptide681–690
El-Hayek and Ikemoto (1998) localized a critical sequence
for mediating skeletal-type E-C coupling to residues 681–
690. We found that p681–690 did not significantly activate
the skeletal muscle CRC at submaximally activating Ca2
(Fig. 5, A and B, circles). Peptide concentrations of 1 M
and 10 M and greater caused inhibition of skeletal (cir-
cles) and cardiac (squares) channel activity, respectively, at
40 mV holding potential but were without a substantial
effect at40 mV. For both isoforms channel inhibition was
the result of a decreased frequency of open events. Elevated
peptide concentrations induced low-conductance substates
at 40 mV holding potential, as indicated by arrows for the
skeletal CRC (Fig. 5 A, left panel).
Peptide681–685
A cluster of five positively charged amino acids (residues
681–685) in the II-III loop has been postulated to be part of
the domain that interacts with the skeletal CRC (Gurrola et
al., 1999). Fig. 6 shows the effects of p681–685 on submaxi-
mally Ca2-activated skeletal CRCs. Peptide681–685 in-
duced long-lasting channel closings at 40 mV holding
potential. At 40 mV, the peptide increased the number of
channel events. However, current amplitude histogram anal-
ysis revealed that the additional events represented a sub-
conductance of 60% of the control full conductance in the
presence of 10 or 30 M p681–685 (second and third traces
in right column). No increase in the frequency of the fully
open state, as determined for full-length II-III loop peptide,
p671–680, and p720–765 was recorded in the presence of
p681–685. An essentially identical behavior was observed for
cardiac muscle CRCs (data not shown).
FIGURE 4 Effects of p671–680 on submaximally Ca2-activated skeletal
muscle and cardiac muscle CRC activities. (A) Shown are six recordings
from one experiment with three skeletal muscle CRCs. Single channel
currents, shown as downward or upward deflections from closed levels
(marked “C”), were recorded as in Fig. 2. (B) Relative mean Po values
(SE) from 6 to 15 experiments with skeletal (circles) and from three to
four experiments with cardiac (squares) CRCs at holding potentials of40
mV (open symbols) and 40 mV (closed symbols). (C) Relative mean Po
values from 8 to 11 experiments with skeletal CRCs under more physio-
logical conditions using symmetrical 150 mM KCl and 10 mM lumenal
Ca2 as current carrier at 0 mV holding potential. The mean open proba-
bility used in the calculation of the Po/PoControl ratios was 0.0024 0.0004
(n 	 15). To decrease noise, channel recordings were filtered at 300 Hz
before analysis. *Significantly different (p  0.05) from control as deter-
mined by ANOVA and Dunnett’s method.
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Peptide720–765
Expression of chimeric cDNAs in dysgenic myotubes and
studies with DHPR-derived peptides have revealed a second
region (residues 711–765) in the skeletal II-III loop of
DHPR 1-subunit that interacts with the skeletal CRC (El-
Hayek et al., 1995; Nakai et al., 1998; Saiki et al., 1999),
with conflicting roles ascribed to this region. Expression
studies suggest an agonist function (Nakai et al., 1998),
whereas peptide studies suggest a blocking function for
DHPR residues 724–760 in skeletal muscle E-C coupling
(Saiki et al., 1999). Fig. 7 A shows that p720–765 activated
submaximally Ca2-activated skeletal CRCs in single chan-
nel measurements. The activity of the channels progres-
sively increased at both holding potentials as the peptide
concentration was increased from 0.3 M to 30 M (Fig. 7
A). The increase in channel activity was due to an increase
in the number of open events rather than an increase in
mean open times. In separate experiments we determined
that the activating effect of this peptide on skeletal CRCs
was reversible (data not shown). Thirty M p720–765 in-
creased skeletal CRCs activity8-fold compared to control
levels (Fig. 7 B, circles) while no significant activation of
cardiac CRC activity was observed in the tested peptide
range from 100 nM to 30 M (Fig. 7 B, squares). To
confirm skeletal CRC stimulation by p720–765 under more
physiological conditions, single channel measurements
were recorded at 0 mV holding potential in symmetrical 150
mM KCl with 10 mM lumenal Ca2 as current carrier. Fig.
7 C summarizes results from five to six experiments with 3,
10, and 30 M cytosolic p720–765. We observed a concen-
tration-dependent activation of submaximally Ca2-acti-
vated skeletal CRCs with an 20-fold activation in the
presence of 30 M p720–765.
Effects of truncated DHPR II-III loop peptides
on maximally Ca2-activated skeletal and
cardiac CRCs
The potential of the peptides to induce subconductances in
skeletal and cardiac CRCs was further examined under
maximally Ca2-activating conditions at a free cytosolic
and lumenal Ca2 concentration of 20 M. At this Ca2
concentration both channel isoforms are maximally acti-
vated by Ca2 under the recording conditions used in this
study (Xu et al., 1998). Addition of the full-length II-III
loop peptide, p671–680 or p720–765, to maximally Ca2-acti-
vated skeletal or cardiac CRCs did not result in any detect-
FIGURE 5 Effects of p681–690 on submaximally Ca2-activated skeletal
muscle CRC. (A) Shown are eight recordings from one experiment with
two skeletal CRCs at 0 (Control) and the indicated peptide concentrations.
Single channel currents, shown as upward or downward deflections from
closed levels (marked “C”), were recorded as in Fig. 2. (B) Relative mean
Po values (SE) from four to eight experiments using skeletal (circles) and
four to five experiments using cardiac CRCs (squares) at holding potentials
of 40 mV (open symbols) and 40 mV (closed symbols). *Significantly
different (p 0.05) from control as determined by ANOVA and Dunnett’s
method.
FIGURE 6 Effects of p681–685 on submaximally Ca2-activated skeletal
muscle CRC. Shown are six recordings from one representative (n 	 4)
experiment with one skeletal CRC at 0 (Control) and the indicated peptide
concentrations. Single channel currents, shown as upward or downward
deflections from closed levels (marked “C”), were recorded as in Fig. 2.
Current amplitude histograms on the right indicate that the peptide induces
at 40 mV a substate corresponding to 60% of the control full conduc-
tance.
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able subconductances (data not shown). However, p671–690,
p681–690, and p681–685, all of which contain a cluster of five
positively charged amino acids, induced subconductance
states in both skeletal and cardiac CRCs reminiscent of
those observed in submaximally Ca2-activated channels.
At cytosolic concentrations in excess of 0.5 M, p671–690,
p681–690, and p681–685 induced subconductance states in
maximally Ca2-activated skeletal and cardiac CRCs. Rep-
resentative current traces and the corresponding current
amplitude histograms are shown for skeletal (Fig. 8 A) and
cardiac CRCs (Fig. 8 B). Channels were recorded at 40
mV and40 mV holding potentials in the absence (control)
or presence of 10 M p671–690 (first and second two traces
in Fig. 8, A and B), p681–690 (third two traces), and p681–685
(fourth two traces). The peptides induced a large number of
different subconductances as identified by visual inspection
of current traces. Subsets of consistently observed major
substates were calculated as means  SE from four to five
amplitude histograms and are listed in Table 1. The two
predominant substates induced by p671–690 at 40 mV had
conductances of 6.8 1.1% and 13.1 1.7% of the control
full conductance. Additionally, long-lasting channel clos-
ings were observed at this holding potential (not shown).
FIGURE 7 Effects of p720–765 on submaximally Ca2-activated skeletal
muscle and cardiac muscle CRC activities. (A) Shown are eight recordings
from one experiment with three skeletal CRCs. Single channel currents,
shown as downward or upward deflections from closed levels (marked
“C”), were recorded as in Fig. 2 at40 mV (left panel) and40 mV (right
panel) holding potentials at 0 (Control) and the indicated peptide concen-
trations. (B) Relative mean Po values (SE) from 4 to 11 experiments with
skeletal CRCs (circles) and 9–17 experiments with cardiac CRCs
(squares) at different peptide concentrations at 40 mV (open symbols)
and 40 mV (closed symbols) holding potentials. (C) Relative mean Po
values from five to six experiments with skeletal CRCs under more
physiological conditions using symmetrical 150 mM KCl and 10 mM
lumenal Ca2 as current carrier at 0 mV holding potential. The mean open
probability used in the calculation of the Po/PoControl ratios was 0.0037 
0.0025 (n 	 8). To decrease noise, channel recordings were filtered at 300
Hz before analysis. *Significantly different (p  0.05) from control as
determined by ANOVA and Dunnett’s method.
FIGURE 8 Truncated DHPR 1-subunit II-III loop peptides containing
the sequence RKRRK induce similar subconductances in maximally Ca2-
activated skeletal (A) and cardiac (B) CRCs at 40 mV and 40 mV
holding potentials. The cytosolic and lumenal free Ca2 concentrations
were 20 M. Three truncated peptides, p671–690, p681–690, and p681–685,
induced subconductances and long channel closings. The major subcon-
ductance states induced by the peptides are shown in the accompanying
current amplitude histograms, and are summarized in Table 1. The control
traces and current amplitude histograms are from an experiment in which
the effects of 10 M p671–690 were tested. The control traces and current
amplitude histograms for experiments in the presence of p681–690 and
p681–685 (not shown) were very similar to the one shown.
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Peptide671–690 induced four predominant substates at 40
mV holding potential with conductances of 31.2  2.0%,
45.2  4.7%, 63.3  2.1%, and 86.6  0.8% of control full
conductance. Peptide681–690 and p681–685 showed similar
substate behavior, as a majority of the subconductances
induced by these two peptides were close to those induced
by p671–690 (Table 1). Moreover, p671–690, p681–690, and
p681–685 induced subconductance states in the cardiac
CRC that were similar to those induced in the skeletal CRC
at positive and negative holding potentials (Fig. 8 and
Table 1).
DISCUSSION
In the present study we have investigated various do-
mains of the DHPR 1-subunit II-III loop thought to be
important for conferring skeletal-type E-C coupling.
Comparison of the effects of the full-length II-III loop
peptide and five shorter peptides on single skeletal and
cardiac Ca2 release channels allowed us to identify two
regions (p671–680 and p720–765) that specifically activate
the skeletal muscle CRC under physiologically relevant
conditions. The finding that p720–765 specifically acti-
vates the submaximally Ca2-activated skeletal CRC
identifies a region of the DHPR II-III loop that has also
been suggested by previous in vivo studies using dys-
genic mice as being important for skeletal-type E-C cou-
pling. Assessment of isoform-specificity at both sub-
maximally and maximally Ca2 activating conditions for
each peptide further suggested that a region
(p681–690), previously implied to confer skeletal-specific
E-C coupling, lacks isoform-specificity and induces sim-
ilar subconductances in both skeletal and cardiac CRCs.
Full-length II-III loop peptide activates skeletal
CRC in a concentration-dependent manner
In agreement with a previous study (Lu et al., 1994), the
DHPR 1-subunit full-length II-III loop peptide activated
the purified skeletal CRC, but not the cardiac CRC, in single
channel recordings. The full-length peptide activated the
skeletal CRC by increasing the number of events, which
suggests an increase in the close3 open transition rate. The
peptide at concentrations of up to 10 M did not induce
subconductance states in either submaximally or maximally
Ca2-activated skeletal or cardiac CRCs. The results con-
firm that the II-III loop of DHPR 1-subunit specifically
interacts with the skeletal CRC.
Activation and inactivation of skeletal CRC by
II-III loop peptides p671–690, p671–680, and p681–690
Previous in vitro studies have suggested that residues 671–
690 are critical for skeletal-type E-C coupling (El-Hayek et
al., 1995; Gurrola et al., 1999; Dulhunty et al., 1999). At
concentrations 10 M, p671–690 activated the skeletal
CRC, whereas concentrations of 10 M were inhibitory.
El-Hayek and Ikemoto (1998) further localized the critical
sequence to residues 681–690. A cluster of five positively
charged residues RKRRK (residues 681–685) present in
p671–690 and p681–690 was suggested to be essential for
activation of the skeletal CRC by p671–690 and p681–690
(El-Hayek and Ikemoto, 1998; Zhu et al., 1999). Structural
analysis using NMR indicated that p671–690 consists of a
helical segment extending from the N-terminus to Lys685,
followed by an unstructured region extending to the C-
terminus (Casarotto et al., 2000). Thus, the cluster RKRRK
is located in the region of the peptide that is structured,
whereas in a shorter peptide (residues 681–687) RKRRK
showed little if any structure. This may explain why this
cluster by itself was only minimally effective in increasing
channel activity (El-Hayek and Ikemoto, 1998; Casarotto et
al., 2000). However, a role for this cluster was indicated by
the observation that its interruption by a single negatively
charged residue (R684E) abolished the increase in [3H]ry-
anodine binding otherwise observed with the unmodified
p666–690 (Gurrola et al., 1999). Conversely, formation of a
cluster of five positively charged residues (substitution of a
glutamate with a lysine) in an inactive cardiac peptide
corresponding to skeletal p681–690 yielded an active peptide
that induced subconductances in skeletal CRC (Zhu et al.,
1999).
Our results confirm that p671–690 can activate and inhibit
the skeletal CRC depending on peptide concentration. How-
ever, we find that the region in p671–690 that specifically
interacts with the skeletal CRC resides in residues 671–680
as p671–680 activated the submaximally Ca2-activated skel-
etal, but not cardiac, CRC. To our knowledge, the effects of
p671–680 on the skeletal and cardiac CRCs have not been
TABLE 1 Subconductances in maximally Ca2-activated
skeletal and cardiac CRCs induced by DHPR 1-subunit II-III
loop peptides containing a cluster of five positively charged
amino acids
Peptide
Skeletal CRC Cardiac CRC
40 mV 40 mV 40 mV 40 mV
p671-690 6.8  1.1 31.2  2.0
13.1  1.7 45.2  4.7 11.6  2.9 42.4  2.3
63.3  2.1 64.8  1.0
86.6  0.8
p681-690 4.8  0.9 14.7  4.4 5.6  0.7 16.2  1.8
36.1  4.1
48.7  3.1 43.4  2.8
62.5  2.2 61.6  5.0
86.5  2.1
p681-685 11.9  1.8 45.0  3.2 14.0  5.0 53.9  2.9
27.6  1.3 61.5  1.1 25.0  2.8 84.6  6.2
Subconductances are given as percent of control (no peptide) conduc-
tances. Data are the mean SE of four to five experiments.
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documented previously. In contrast, p681–690 interacted iso-
form-independently with the channels inducing substates in
the skeletal and cardiac CRCs that were not observed for the
full-length II-III loop peptide. A long mean open time of the
subconductances could provide an explanation for the ob-
servation that the peptide increased [3H]ryanodine binding
to and SR Ca2 release from skeletal SR vesicles (El-Hayek
and Ikemoto, 1998; Gurrola et al., 1999; Zhu et al., 1999).
In addition to lacking isoform-specificity, the proposed role
of aa 681–690 was questioned by a recent report showing
that microinjection of a construct with a scrambled se-
quence in residues 681–690 resulted in skeletal E-C cou-
pling (Proenza et al., 2000). Thus, this study, which was
published after the original submission of our work, also
suggests that aa 681–690 are not crucial for conferring
skeletal-specific E-C coupling.
The relevance of our finding concerning the role of aa
671–680 is at variance with expression studies in dysgenic
myotubes. Microinjection of skeletal muscle and cardiac
DHPR chimeric constructs into dysgenic myotubes indi-
cated that residues 666–709 of the II-III cytoplasmic loop of
the skeletal muscle DHPR 1-subunit are not crucial skel-
etal muscle E-C coupling (Nakai et al., 1998). However, it
is conceivable that due to 70% sequence identity in the
N-terminal part of the DHPR II-III loop, studies with skel-
etal/cardiac chimeras may have failed to detect a role of aa
671–680 in mediating skeletal-type E-C coupling. Ulti-
mately, the physiological relevance of our findings regard-
ing p671–680 remains to be determined using a cellular
system.
Peptide666–791 contains a second critical
sequence for activating the skeletal CRC
Expression of skeletal muscle and cardiac DHPR chimeric
constructs in dysgenic myotubes indicated that a 17-amino
acid region (residues 725–742) of the putative II-III cyto-
plasmic loop of the DHPR 1-subunit is a weak determinant
of skeletal muscle E-C coupling (Nakai et al., 1998). Skel-
etal-type coupling was stronger in a chimera containing
skeletal residues 711–765. These results are difficult to
reconcile with observations that p724–760 by itself had no
effect, but antagonized the activating effects and conforma-
tional changes induced by both p671–690 and T-tubule depo-
larization (El-Hayek et al., 1995; Saiki et al., 1999). Based
on this evidence, Saiki et al. (1999) proposed that depolar-
ization-induced activation of E-C coupling is mediated by
the binding of an activator located in the II-III loop corre-
sponding to p671–690 to the skeletal CRC. Binding of a
blocker/reprimer located in residues 724–760 to the same or
another region of skeletal CRC removes the activator from
its site(s) during T-tubule polarization. In contrast, Nakai et
al. (1998) speculated that the midregion of the II-III loop
(residues 725–742) might be an agonist that assumes the
right configuration to bind to and activate the CRC only
when the sarcolemma is depolarized. Our single channel
studies support the model by Nakai et al. (1998) by showing
that p720–765 specifically activated the submaximally Ca2-
activated skeletal CRC at micromolar concentrations. We
conclude that the skeletal II-III loop contains two segments,
residues 671–680 and 720–765, that specifically activate
the skeletal CRC.
Induction of subconductance states in skeletal
and cardiac CRCs
Our results suggest that the three peptides, p671–690,
p681–690, and p681–685, that all contain a cluster of five
positively charged residues, interact with both the skeletal
and the cardiac CRCs. Elevated levels of p671–690 and
p681–690 inhibited the submaximally Ca2-activated skeletal
and cardiac CRCs and formed detectable subconductance
states at40 mV at concentrations in excess of 0.5 M. All
three peptides induced subconductance states in both chan-
nel isoforms at 40 mV and 40 mV under maximally
Ca2-activating conditions. Peptide671–680, which does not
contain a cluster of positive charges, failed to induce sub-
conductances in skeletal and cardiac CRCs.
One explanation for the subconductances is that the short
positively charged peptides enter the wide cytosolic vesti-
bule of the CRCs (Radermacher et al., 1994; Serysheva et
al., 1995) and bind to site(s) inaccessible for larger peptides
containing the RKRRK motif (i.e., the full-length II-III loop
peptide) and cause a partial block of the ion conductance
pathway. Similar mechanisms have been proposed for other
small basic peptides (Mead et al., 1998; Tripathy et al.,
1998), large tetraalkyl ammonium ions (Tinker et al., 1992)
and charged local anesthetics (Tinker and Williams, 1993;
Xu et al., 1993) to explain subconductances in the skeletal
and cardiac CRCs. In a recent study, the p671–690-induced
block of the skeletal CRC could be reversed by an increased
permeant cation concentration in the trans (SR lumenal)
bilayer chamber, also suggesting that the peptides can enter
the cytoplasmic vestibule to induce subconductances (Dul-
hunty et al., 1999).
It is noteworthy that the motif RKRRK is also found in
Imperatoxin A (IpTxa), a 33-amino acid peptide isolated
from the scorpion Pandinus imperator, which induces volt-
age-dependent subconductance states in both skeletal and
cardiac CRCs (Tripathy et al., 1998). It has been suggested
that IpTxa mimics the effects of II-III loop peptides as it
displays structural and functional similarities with residues
666–690 of the skeletal DHPR 1-subunit II-III loop (Gur-
rola et al., 1999). The toxin binds with nanomolar affinity to
skeletal CRC (Gurrola et al., 1999) at a cytoplasmic site 11
nm from the transmembrane pore (Samso et al., 1999). The
presence of a common motif of basic residues in IpTxa and
the three truncated II-III loop peptides (p671–690, p681–690,
and p681–685) raises the possibility that the peptides do not
act as channel blockers, but rather bind to regions outside
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the channel pore, and induce subconductance states by a
conformational change.
In conclusion, the present study shows that the DHPR
1-subunit II-III loop has two regions, residues 671–680
and 720–765, that specifically activate the skeletal CRC. A
II-III loop region containing a cluster of five positively
charged residues (aa 681–685) induces subconductances in
both skeletal and cardiac CRCs. The finding of an isoform-
independent interaction among p671–690, p681–690, p681–685,
and CRCs suggests that the action of these peptides, while
interesting from a biophysical point of view, could be un-
related to cellular function.
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